|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
ANT2 can be used as a marker of dedifferentiated pathology and aggressiveness of cancer.
|
30225759 |
2019 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
ANT2 can be used as a marker of dedifferentiated pathology and aggressiveness of cancer.
|
30225759 |
2019 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
ANT2 induced the formation of cancer-initiating cell (CIC) phenotypes and promoted metastasis-associated traits in the Huh7 cells.
|
28350139 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
ANT2 induced the formation of cancer-initiating cell (CIC) phenotypes and promoted metastasis-associated traits in the Huh7 cells.
|
28350139 |
2017 |
|
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
|
28350139 |
2017 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
These findings suggest that ANT2 overexpression contributes to EGFR-TKI resistance in NSCLC and that ANT2 targeting may be considered a novel strategy for overcoming this resistance.Mol Cancer Ther; 15(6); 1387-96.©2016 AACR.
|
26883272 |
2016 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
These findings suggest that ANT2 overexpression contributes to EGFR-TKI resistance in NSCLC and that ANT2 targeting may be considered a novel strategy for overcoming this resistance.Mol Cancer Ther; 15(6); 1387-96.©2016 AACR.
|
26883272 |
2016 |
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
Our data show that miR-19a and miR-96, whose expression is regulated by ANT2 suppression, were markedly upregulated in HCC cell lines and clinical samples.
|
27012708 |
2016 |
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
ANT2 suppression by shRNA may be able to exert anticancer effects in HCC further by restoring SOCS1 expression.
|
23242177 |
2013 |
|
Liver carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The data suggest that miR-636 might function as a tumor suppressor miRNA affecting HCC tumorigenesis via downregulation of Ras, and that ANT2 suppression by shRNA could exert an anticancer effect by restoring miR-636 expression in HCC.
|
23306701 |
2013 |
|
Liver carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Our results suggest that the combined RNA interference with ANT2 and GCV therapy inhibited hepatocellular carcinoma cell proliferation more than single GCV therapy or ANT2 shRNA therapy in vitro and in vivo.
|
24054501 |
2013 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
ANT2 suppression by shRNA might be exploited to overcome TRAIL-resistance in cancer.
|
20875141 |
2010 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
ANT2 suppression by shRNA might be exploited to overcome TRAIL-resistance in cancer.
|
20875141 |
2010 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
These data provide the first argument for the involvement of the ANT2 protein in glycolytic ATP uptake in cancer cell mitochondria and suggest a possible ANT2 antisense strategy for cancer therapy.
|
8688152 |
1996 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
These data provide the first argument for the involvement of the ANT2 protein in glycolytic ATP uptake in cancer cell mitochondria and suggest a possible ANT2 antisense strategy for cancer therapy.
|
8688152 |
1996 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Additionally, we modulated ANT2 expression levels using ANT2 siRNA and an ANT2 expression vector in cancer cells and murine xenografted tumors.
|
30225759 |
2019 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
ANT2 shRNA downregulates miR-19a and miR-96 through the PI3K/Akt pathway and suppresses tumor growth in hepatocellular carcinoma cells.
|
27012708 |
2016 |
|
Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
We treated the tumor cells with ANT2 shRNA or GCV or both ANT2 shRNA and GCV and treated the in vivo mouse model with a Huh 7/NTG tumor xenograft.
|
24054501 |
2013 |
|
Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Since the expression of ANT2 is closely linked to the mitochondrial bioenergetics of tumors, it should be taken into account for individualizing cancer treatments and for the development of anticancer strategies.
|
20950584 |
2011 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We utilized the adeno- ANT2 shRNA virus to inhibit ANT2 expression and then observed the treatment effect in a SP of breast cancer cell line.
|
22198296 |
2012 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We utilized the adeno- ANT2 shRNA virus to inhibit ANT2 expression and then observed the treatment effect in a SP of breast cancer cell line.
|
22198296 |
2012 |
|
Malignant neoplasm of breast
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We utilized an ANT2 vector-based RNA interference approach to inhibition of ANT2 expression, and the HER2/neu-overexpressing human breast cancer cell line, SK-BR3, was used throughout the study.
|
20650008 |
2010 |
|
Malignant neoplasm of breast
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the present study, we examined the effect of RNA shRNA-induced suppression of ANT2 on the resistance of breast cancer cells to TRAIL-induced apoptosis in vitro and in vivo.
|
20875141 |
2010 |
|
Breast Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In the present study, we examined the effect of RNA shRNA-induced suppression of ANT2 on the resistance of breast cancer cells to TRAIL-induced apoptosis in vitro and in vivo.
|
20875141 |
2010 |
|
Breast Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
We utilized an ANT2 vector-based RNA interference approach to inhibition of ANT2 expression, and the HER2/neu-overexpressing human breast cancer cell line, SK-BR3, was used throughout the study.
|
20650008 |
2010 |